Scpharmaceutical Stock Price, News & Analysis

scPharmaceuticals Inc. (Nasdaq: SCPH) announced FDA acceptance of their FUROSCIX NDA, scheduled for review on October 8, 2022. The company is preparing for a Q4 2022 launch, pending approval. Financially, scPharmaceuticals ended Q2 2022 with $56 million in cash, down from $75.5 million at year-end 2021. They reported a net loss of $9.7 million for Q2 2022, up from $7.1 million in Q2 2021. Research and development expenses rose to $5.1 million, and general and administrative expenses increased to $4.3 million. The company projects a net loss between $43 million and $48 million for 2022.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will participate in a panel discussion on heart failure therapeutics on July 14, 2022, at 10:00 a.m. ET. The event is hosted by Maxim Group LLC and will be available live on M-Vest. The company is dedicated to developing products that enhance infused therapy delivery, improve patient care, and lower healthcare costs. Their focus includes self-administered IV-strength treatments for heart failure and infectious diseases.

scPharmaceuticals Inc. (SCPH) announced positive results from its AT HOME-HF Pilot study, evaluating FUROSCIX for chronic heart failure patients. The study showed a 37% reduction in heart failure hospitalizations and improvements in symptoms and quality of life. Subjects using FUROSCIX experienced greater weight loss and higher Kansas City Cardiomyopathy Questionnaire scores. Although there were some mild adverse events, the tolerability profile was deemed acceptable. With a PDUFA date set for October 8, 2022, the company aims for a Q4 2022 commercial launch of FUROSCIX, pending regulatory approval.

scPharmaceuticals Inc. (SCPH) is hosting a virtual investor event on July 13, 2022, at 10:00 AM EDT to discuss FUROSCIX (furosemide) 80mg/10mL, an investigational treatment for heart failure patients. Key Opinion Leaders Dr. Daniel Bensimhon and James Kenney will present insights on the treatment landscape and the economic implications of heart failure management. The event will also feature discussions from scPharmaceuticals' leadership about the potential benefits of FUROSCIX in reducing healthcare costs and improving patient care.

scPharmaceuticals (Nasdaq: SCPH) announced two abstracts from the FREEDOM-HF study will be presented at the AAHFN Annual Meeting in Orlando on June 15-18. The study's primary results indicate that patients treated with FUROSCIX incurred nearly $18,000 less in 30-day heart failure-related costs compared to traditional inpatient care. The New Drug Application for FUROSCIX is under review, with a Prescription Drug User Fee Act date set for October 8, 2022. The company is gearing up for a potential Q4 2022 commercial launch if approved.

scPharmaceuticals Inc. (Nasdaq: SCPH) has announced that CEO John Tucker will present at the Jefferies Healthcare Conference on June 9, 2022, at 2:00 PM EDT in New York City. The presentation will focus on the company's mission to develop and commercialize products aimed at optimizing therapies and reducing healthcare costs. A live webcast will be available on their website under the Investor Relations section. Headquartered in Burlington, MA, scPharmaceuticals specializes in outpatient treatments for acute conditions, particularly in heart failure and infectious diseases.

scPharmaceuticals Inc. (Nasdaq: SCPH), a company dedicated to innovative healthcare solutions, announced its CEO John Tucker will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 3:00 PM EDT in Miami, FL. The conference aims to highlight advancements in outpatient care and healthcare cost reduction. A live webcast of the presentation will be available on the company's Investor Relations webpage. scPharmaceuticals specializes in developing products for outpatient care, focusing on IV-strength treatments for heart failure and infectious diseases.

scPharmaceuticals reported a net loss of $7.7 million for Q1 2022, compared to $7.1 million in Q1 2021. Cash, cash equivalents, and investments totaled $65.6 million, down from $75.5 million at the end of 2021, but sufficient to fund operations into 2023. The FDA set a PDUFA action date for FUROSCIX at October 8, 2022, with a potential commercial launch in Q4 2022 if approved. The company is ramping up commercial readiness, including finalizing pricing research and distribution partnerships.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that the FDA has accepted its New Drug Application for FUROSCIX, a formulation of furosemide delivered via an on-body infusor, targeting treatment for heart failure-related congestion. The FDA set a PDUFA action date for October 8, 2022. CEO John Tucker highlighted that FUROSCIX addresses a critical healthcare need and may lead to significant cost savings. The company is preparing for a potential Q4 2022 commercial launch contingent on FDA approval.